Loading...

REPL REPLIMUNE GROUP INC Legal Disputes 8-K Filing

RPLM

RPL

REPLIMUNE GROUP INC

(REPL)

2026 8-K

FDA Response Letter

Loan Agreement Update

Corporate Update

Financial Results Released

FDA Resubmission Accepted

FDA Meeting Update

Stockholders Meeting Results

Financial Statements

Pre-Market Approval

Investor Meetings

Financial Statements

Board Appointment

Financial Results

Warrant Adjustment

Stock Offering Update

Financial Results

Financial Results and Corpo...

Securities Purchase Agreement

Data Updates and Topline Re...

Data Updates Announcement

Financial Results Announcement

Executive Leadership Transi...

Results of Operations and F...

Clinical Data Presentation

Loan Agreement Amendment

Data Updates and Developmen...

Earnings Reports

Appointment of CFO

Annual Meeting of Stockholders

Sales Agreement with Leerin...

Financial Results and Colla...

Appointment of Director

Financial Results and CFO R...

Regulation FD Disclosure

Earnings Reports

Management Changes

External Links:

On April 10, 2026, Replimune Group, Inc. announced it received a second Complete Response Letter from the FDA regarding its BLA for RP1 (vusolimogene oderparepvec) combined with nivolumab for advanced melanoma treatment.

AI Assistant

REPLIMUNE GROUP INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.